Clinical Daily Summary
Clinical Daily Summary: What Happened on November 17, 2026
Safusidenib showed sustained activity in a 27-person glioma study
Rein shared preliminary, blinded week-12 lung-function and safety findings for its inhaled IPF drug.
Today in brief
In 27 people with grade 2 IDH1-mutant glioma, safusidenib had an 81.5% confirmed clinical benefit rate, with median drug exposure of 46.7 months.1 Rein reported preliminary week-12 findings from its ongoing Phase II trial of inhaled LTI-03, with no serious treatment-emergent adverse events in the initial blinded review.2
Also worth knowing
-
Central review in Nuvation Bio’s Phase II J201 study found a 51.9% confirmed objective response rate. Adverse events led three patients to stop treatment, and the company is advancing a Phase III study.1
-
Of 24 evaluable participants in Rein’s initial blinded review, eight had improved forced vital capacity at week 12, while 11 had a decline of no more than 5.7%. The company expects unblinded top-line results in 2027.2